Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denise M Wolf

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast CancerMark Jesus M Magbanua, Christina Yau, Denise M Wolf, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2018
Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)Mark Jesus M Magbanua, Hope S Rugo, Denise M Wolf, et al.
Breast Cancer Research and Treatment|August 10, 2012
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibAnneleen Daemen, Denise M Wolf, James E Korkola, et al.
NPJ Breast Cancer|March 26, 2021
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence riskMark Jesus M Magbanua, Wen Li, Denise M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim R M Blenman, Michal Marczyk, Thomas Karn, et al.
NPJ Breast Cancer|September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Ashish Sanil, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Tomography (Ann Arbor, Mich.)|March 26, 2025
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast CancerWen Li, Natsuko Onishi, Jessica E Gibbs, et al.
JCO Precision Oncology|September 11, 2020
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALJulia D Wulfkuhle, Christina Yau, Denise M Wolf, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast CancerMark Jesus M Magbanua, Christina Yau, Denise M Wolf, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2018
Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance)Mark Jesus M Magbanua, Hope S Rugo, Denise M Wolf, et al.
Breast Cancer Research and Treatment|August 10, 2012
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibAnneleen Daemen, Denise M Wolf, James E Korkola, et al.
NPJ Breast Cancer|March 26, 2021
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence riskMark Jesus M Magbanua, Wen Li, Denise M Wolf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2022
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast CancerKim R M Blenman, Michal Marczyk, Thomas Karn, et al.
NPJ Breast Cancer|September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Ashish Sanil, et al.
Breast Cancer Research : BCR|August 31, 2017
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant settingTesa M Severson, Denise M Wolf, Christina Yau, et al.
Tomography (Ann Arbor, Mich.)|March 26, 2025
MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast CancerWen Li, Natsuko Onishi, Jessica E Gibbs, et al.
JCO Precision Oncology|September 11, 2020
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALJulia D Wulfkuhle, Christina Yau, Denise M Wolf, et al.
Pageof 7